FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078761085> ?p ?o ?g. }

• W2078761085 endingPage "16" @default.
• W2078761085 startingPage "6" @default.
• W2078761085 abstract "In a substudy of the HORIZON pivotal fracture trial, in which yearly intravenous zoledronic acid 5 mg was found to significantly reduce risk of various fracture types in patients with postmenopausal osteoporosis, 152 patients underwent bone biopsy. Zoledronic acid reduced bone turnover by 63% and preserved bone structure and volume, with evidence of ongoing bone remodeling in 99% of biopsies obtained. Introduction: In the HORIZON pivotal fracture trial (PFT), enrolling 7736 women with postmenopausal osteoporosis, three annual intravenous infusions of the bisphosphonate zoledronic acid (5 mg) significantly reduced morphometric vertebral, clinical vertebral, hip, and nonvertebral fractures by 70%, 77%, 41%, and 25%, respectively. Whereas 79% of patients received zoledronic acid/placebo only (stratum I, n = 6113), 21% received concomitant treatment with other antiresorptive drugs, excluding other bisphosphonates, PTH, and strontium (stratum II, n = 1652). Materials and Methods: To determine effects on bone remodeling and bone architecture, iliac crest bone biopsies were obtained in 152 patients on active treatment or placebo at 3 yr after double tetracycline labeling. In five patients, only qualitative histology was performed, leaving 147 biopsy cores (79 on active treatment and 68 on placebo) for νCT analysis and histomorphometry. Results: Analysis of bone structure by νCT revealed higher trabecular bone volume (BV/TV) in the zoledronic acid group (median, 16.6% versus 12.8%; p = 0.020). In addition, patients treated with zoledronic acid exhibited higher trabecular numbers (p = 0.008), decreased trabecular separation (p = 0.011), and a trend toward improvement in connectivity density (p = 0.062), all indicating better preservation of trabecular structure after treatment with zoledronic acid. Qualitative analysis revealed presence of tetracycline label in 81 of 82 biopsies from patients on zoledronic acid and all 70 biopsies from placebo patients, indicative of continued bone remodeling. No bone pathology was observed. Zoledronic acid induced a 63% median (71% mean) reduction of the activation frequency (Ac.f; p < 0.0001) and reduced mineralizing surface (MS/BS; p < 0.0001) and volume referent bone formation rate (BFR/BV) versus placebo, indicating reduced bone turnover. Mineral appositional rate was higher in the zoledronic acid group (p = 0.0002), suggesting improved osteoblast function compared with placebo. Mineralization lag time was similar in the two groups, whereas osteoid volume (OV/BV; p < 0.0001) and osteoid thickness (O. Th; p = 0.0094) were lower in zoledronic acid-treated patients, indicating normal osteoid formation and mineralization of newly formed bone. Concomitant administration of other antiresorptive osteoporosis therapies (e.g., raloxifene, tamoxifen, tibolone, ipriflavone) did not significantly alter the tissue level response to zoledronic acid. Conclusions: Annual dosing for 3 yr with zoledronic acid 5 mg intravenously resulted in a median 63% (mean, 71%) reduction of bone turnover and preservation of bone structure and mass without any signs of adynamic bone. Concomitant treatment with other osteoporosis therapies did not significantly affect the bone response to zoledronic acid." @default.
• W2078761085 created "2016-06-24" @default.
• W2078761085 creator A5007875733 @default.
• W2078761085 creator A5010443326 @default.
• W2078761085 creator A5013115644 @default.
• W2078761085 creator A5020174799 @default.
• W2078761085 creator A5025974023 @default.
• W2078761085 creator A5027426647 @default.
• W2078761085 creator A5030361963 @default.
• W2078761085 creator A5037555787 @default.
• W2078761085 creator A5049691512 @default.
• W2078761085 creator A5052478195 @default.
• W2078761085 creator A5054573386 @default.
• W2078761085 creator A5054673344 @default.
• W2078761085 creator A5055745265 @default.
• W2078761085 creator A5058464240 @default.
• W2078761085 creator A5067955208 @default.
• W2078761085 date "2007-09-10" @default.
• W2078761085 modified "2023-10-09" @default.
• W2078761085 title "Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure" @default.
• W2078761085 cites W1964756955 @default.
• W2078761085 cites W1964983194 @default.
• W2078761085 cites W1972567449 @default.
• W2078761085 cites W1974395735 @default.
• W2078761085 cites W1977271471 @default.
• W2078761085 cites W1978228601 @default.
• W2078761085 cites W1984592620 @default.
• W2078761085 cites W1989783674 @default.
• W2078761085 cites W1990771263 @default.
• W2078761085 cites W1992637537 @default.
• W2078761085 cites W1993035292 @default.
• W2078761085 cites W1996683346 @default.
• W2078761085 cites W2006951696 @default.
• W2078761085 cites W2021791228 @default.
• W2078761085 cites W2023781848 @default.
• W2078761085 cites W2050955465 @default.
• W2078761085 cites W2052524297 @default.
• W2078761085 cites W2059180322 @default.
• W2078761085 cites W2064081312 @default.
• W2078761085 cites W2065667561 @default.
• W2078761085 cites W2068747322 @default.
• W2078761085 cites W2075660804 @default.
• W2078761085 cites W2087378917 @default.
• W2078761085 cites W2088924780 @default.
• W2078761085 cites W2118676056 @default.
• W2078761085 cites W2137868736 @default.
• W2078761085 cites W2140312400 @default.
• W2078761085 cites W2151942524 @default.
• W2078761085 cites W2159837057 @default.
• W2078761085 doi "https://doi.org/10.1359/jbmr.070906" @default.
• W2078761085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17892374" @default.
• W2078761085 hasPublicationYear "2007" @default.
• W2078761085 type Work @default.
• W2078761085 sameAs 2078761085 @default.
• W2078761085 citedByCount "196" @default.
• W2078761085 countsByYear W20787610852012 @default.
• W2078761085 countsByYear W20787610852013 @default.
• W2078761085 countsByYear W20787610852014 @default.
• W2078761085 countsByYear W20787610852015 @default.
• W2078761085 countsByYear W20787610852016 @default.
• W2078761085 countsByYear W20787610852017 @default.
• W2078761085 countsByYear W20787610852018 @default.
• W2078761085 countsByYear W20787610852019 @default.
• W2078761085 countsByYear W20787610852020 @default.
• W2078761085 countsByYear W20787610852021 @default.
• W2078761085 countsByYear W20787610852022 @default.
• W2078761085 countsByYear W20787610852023 @default.
• W2078761085 crossrefType "journal-article" @default.
• W2078761085 hasAuthorship W2078761085A5007875733 @default.
• W2078761085 hasAuthorship W2078761085A5010443326 @default.
• W2078761085 hasAuthorship W2078761085A5013115644 @default.
• W2078761085 hasAuthorship W2078761085A5020174799 @default.
• W2078761085 hasAuthorship W2078761085A5025974023 @default.
• W2078761085 hasAuthorship W2078761085A5027426647 @default.
• W2078761085 hasAuthorship W2078761085A5030361963 @default.
• W2078761085 hasAuthorship W2078761085A5037555787 @default.
• W2078761085 hasAuthorship W2078761085A5049691512 @default.
• W2078761085 hasAuthorship W2078761085A5052478195 @default.
• W2078761085 hasAuthorship W2078761085A5054573386 @default.
• W2078761085 hasAuthorship W2078761085A5054673344 @default.
• W2078761085 hasAuthorship W2078761085A5055745265 @default.
• W2078761085 hasAuthorship W2078761085A5058464240 @default.
• W2078761085 hasAuthorship W2078761085A5067955208 @default.
• W2078761085 hasConcept C126322002 @default.
• W2078761085 hasConcept C126894567 @default.
• W2078761085 hasConcept C141071460 @default.
• W2078761085 hasConcept C142724271 @default.
• W2078761085 hasConcept C170033053 @default.
• W2078761085 hasConcept C204787440 @default.
• W2078761085 hasConcept C27081682 @default.
• W2078761085 hasConcept C2776326535 @default.
• W2078761085 hasConcept C2776541429 @default.
• W2078761085 hasConcept C2777251235 @default.
• W2078761085 hasConcept C71924100 @default.
• W2078761085 hasConceptScore W2078761085C126322002 @default.
• W2078761085 hasConceptScore W2078761085C126894567 @default.
• W2078761085 hasConceptScore W2078761085C141071460 @default.
• W2078761085 hasConceptScore W2078761085C142724271 @default.

• next